JO
ACAD icon

John Overdeck’s Acadia Pharmaceuticals ACAD Stock Holding History

John Overdeck’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
926,992
+151,871
+20% +$3.34M 0.02% 953
2026
Q1 		$17.3M Sell
775,121
-343,996
-31% -$8.22M 0.01% 1036
2025
Q4 		$29.9M Buy
1,119,117
+453,226
+68% +$10.8M 0.04% 543
2025
Q3 		$14.2M Buy
665,891
+182,793
+38% +$4.32M 0.02% 787
2025
Q2 		$10.4M Sell
483,098
-333,558
-41% -$6.2M 0.02% 806
2025
Q1 		$13.6M Sell
816,656
-426,786
-34% -$7.75M 0.03% 645
2024
Q4 		$22.8M Buy
1,243,442
+133,186
+12% +$2.15M 0.05% 439
2024
Q3 		$17.1M Buy
1,110,256
+762,539
+219% +$12.7M 0.04% 550
2024
Q2 		$5.65M Buy
347,717
+238,288
+218% +$3.85M 0.01% 954
2024
Q1 		$2.02M Sell
109,429
-239,299
-69% -$5.93M ﹤0.01% 1473
2023
Q4 		$10.9M Buy
348,728
+278,628
+397% +$6.65M 0.03% 646
2023
Q3 		$1.46M Sell
70,100
-296,688
-81% -$8.06M ﹤0.01% 1683
2023
Q2 		$8.78M Buy
366,788
+260,588
+245% +$5.79M 0.02% 697
2023
Q1 		$2M Buy
106,200
+95,063
+854% +$1.81M 0.01% 1381
2022
Q4 		$177K Buy
+11,137
New +$174K ﹤0.01% 2417
2022
Q3 		– Sell
-58,800
Closed -$828K – 2436
2022
Q2 		$828K Sell
58,800
-181,671
-76% -$3.39M ﹤0.01% 1623
2022
Q1 		$5.82M Buy
240,471
+214,371
+821% +$5.19M 0.02% 855
2021
Q4 		$609K Buy
26,100
+10,400
+66% +$209K ﹤0.01% 3045
2021
Q3 		$261K Buy
15,700
+1,900
+14% +$36.6K ﹤0.01% 3763
2021
Q2 		$337K Buy
+13,800
New +$311K ﹤0.01% 3420
2020
Q3 		– Sell
-286,618
Closed -$13.9M – 3022
2020
Q2 		$13.9M Buy
+286,618
New +$13.8M 0.07% 301
2020
Q1 		– Sell
-71,480
Closed -$3.06M – 2998
2019
Q4 		$3.06M Sell
71,480
-138,016
-66% -$6M 0.01% 1268
2019
Q3 		$7.54M Buy
209,496
+10,873
+5% +$330K 0.03% 672
2019
Q2 		$5.31M Buy
+198,623
New +$5.07M 0.02% 859
2017
Q1 		– Sell
-49,639
Closed -$1.43M – 2836
2016
Q4 		$1.43M Buy
+49,639
New +$1.31M 0.01% 1744

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's ACAD Position: Q2 2026 in Review

John Overdeck increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q2 2026, buying an estimated $3.34M and bringing the position to 926,992 shares worth $23.5M. The position accounts for 0.02% of the portfolio, ranked #953.

John Overdeck first reported a position in ACAD in Q4 2016 and has held it in 25 quarters since. The position peaked at $29.9M in Q4 2025. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • John Overdeck held 926,992 shares of Acadia Pharmaceuticals worth $23.5M as of Q2 2026.
  • John Overdeck bought 151,871 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.34M.
  • Acadia Pharmaceuticals made up 0.02% of John Overdeck's portfolio in Q2 2026, its #953 holding.
  • John Overdeck first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 25 quarters since.
  • John Overdeck's Acadia Pharmaceuticals position peaked at $29.9M in Q4 2025.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.